The fatty acid synthase inhibitor triclosan: repurposing an anti-microbial agent for targeting prostate cancer by Sadowski, Martin et al.
Oncotarget1www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Advance Publications 2014
The fatty acid synthase inhibitor triclosan: repurposing an anti-
microbial agent for targeting prostate cancer
Martin C. Sadowski1, Rebecca H. Pouwer2, Jennifer H. Gunter1, Amy A. Lubik1,3, 
Ronald J. Quinn2 and Colleen C. Nelson1,3
1 Australian Prostate Cancer Research Centre - Queensland, Institute of Health and Biomedical Innovation, Queensland 
University of Technology, Princess Alexandra Hospital, Translational Research Institute, Brisbane, Australia
2 Eskitis Institute for Drug Discovery, Griffith University, Brisbane, Australia
3 Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, Canada
Correspondence to: Colleen C. Nelson, email: colleen.nelson@qut.edu.au
Keywords: Triclosan, fatty acid synthase, AMPK, lipid metabolism, C75, orlistat, prostate cancer
Received: August 03, 2014 Accepted: September 02, 2014 Published: September 03, 2014
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original author and source are credited. 
ABSTRACT
Inhibition of FASN has emerged as a promising therapeutic target in cancer, 
and numerous inhibitors have been investigated. However, severe pharmacological 
limitations have challenged their clinical testing. The synthetic FASN inhibitor 
triclosan, which was initially developed as a topical antibacterial agent, is merely 
affected by these pharmacological limitations. Yet, little is known about its mechanism 
in inhibiting the growth of cancer cells. Here we compared the cellular and molecular 
effects of triclosan in a panel of eight malignant and non-malignant prostate cell lines 
to the well-known FASN inhibitors C75 and orlistat, which target different partial 
catalytic activities of FASN. Triclosan displayed a superior cytotoxic profile with a 
several-fold lower IC50 than C75 or orlistat. Structure-function analysis revealed 
that alcohol functionality of the parent phenol is critical for inhibitory action. Rescue 
experiments confirmed that end product starvation was a major cause of cytotoxicity. 
Importantly, triclosan, C75 and orlistat induced distinct changes to morphology, 
cell cycle, lipid content and the expression of key enzymes of lipid metabolism, 
demonstrating that inhibition of different partial catalytic activities of FASN activates 
different metabolic pathways. These finding combined with its well-documented 
pharmacological safety profile make triclosan a promising drug candidate for the 
treatment of prostate cancer.
INTRODUCTION
Fatty acid synthase (FASN) is a key metabolic 
enzyme that catalyzes in a stepwise and sequential 
manner the de novo synthesis of fatty acids (FA), 
predominantly palmitate, from the condensation of seven 
molecules of malonyl-CoA and one molecule of acetyl-
CoA. This NADPH-dependent process plays a central 
role in energy homeostasis by converting excess carbon 
intake into FAs for storage [1]. As a homodimeric, 
multifunctional enzyme, FASN employs seven catalytic 
activities (β-ketoacyl synthase, malonyl/acetyl transferase, 
dehydrase, enoyl reductase, β-ketoacyl reductase, and acyl 
carrier protein) during each cycle of FA chain elongation 
before its thioesterase activity releases the ultimate 
product, free palmitate [2].
FASN is expressed at relatively low levels in 
normal cells (except liver, brain, lung and adipose tissue), 
whereas it is highly expressed in a wide variety of cancers, 
including cancer of the prostate, breast, brain, lung, ovary, 
endometrium, colon, thyroid, bladder, kidney, liver, 
pancreas, stomach, oesophagus, eye, mesothelium and 
skin (reviewed in [3]). Elevated expression of FASN has 
been found in the earliest stages of cancer development 
and becomes more pronounced during tumor progression. 
In prostate cancer (PCa), elevated levels of FASN have 
been linked to poor prognosis, reduced disease-free 
survival, aggressiveness of disease, and increased risk 
of death (reviewed in [3]). Despite the presence of high 
levels of circulating dietary FAs, FASN plays a central role 
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in tumor cell development and survival. Knockdown or 
pharmacological inhibition of FASN selectively induces 
cell death of cancer cells and a reduction in tumor volume 
in xenograft mouse models with only a minimal effect 
on normal cells, indicating that FASN is a promising 
target for cancer treatment with the potential for a large 
therapeutic index (reviewed in [4]).
Several natural and synthetic FASN inhibitors 
such as the antifungal agent cerulenin and its synthetic 
derivative C75, the green tea polyphenol epigallocatechin-
3-gallate (EGCG) and other flavonoids (luteolin, 
quercetin, and kaempferol), the β-lactone orlistat as well 
as the bactericide triclosan have been shown to inhibit 
cancer cell growth by inducing cell death (reviewed in 
[4]). Some of these inhibitors have been shown to work 
by directly binding and inhibiting different active sites 
of FASN. For example, cerulenin and C75 interact with 
the β-ketoacyl synthase domain and irreversibly inhibit 
the condensation reaction (reviewed in [4]). In addition, 
C75 was found to also inactivate the enoyl reductase 
and thioesterase partial activities of FASN [5]. EGCG 
acts through competitive binding inhibition of NADPH 
and irreversible inactivation of the β-ketoacyl reductase 
activity [6], orlistat inhibits FASN through formation of 
a covalent adduct with the thioesterase domain [7], and 
triclosan (TCS) binds and inactivates the enoyl reductase 
domain [8]. Given the multi-domain structure of FASN, it 
is not surprising that the cytotoxic effect of various FASN 
inhibitors can have different underlying mechanisms, such 
as end product starvation through depletion of palmitate, 
or toxic accumulation of the FASN substrate malonyl-CoA 
or intermediates of FA synthesis.
Although FASN inhibitors showed promising anti-
cancer activities, their evaluation in clinical trials was 
challenged due to pharmacological limitations. Cerulenin 
was found to be chemically unstable and undesirable for 
use in vivo due to its very reactive epoxy group. This led to 
the development of the chemically more stable, synthetic 
derivative C75 [9]. However, studies in mice revealed 
that C75 and cerulenin cause appetite suppression and 
profound weight loss through direct activation of carnitine 
palmitoyltransferase (CPT-1), which leads to increased 
FA β-oxidation [10]. These concerns have been addressed 
with the development of C93, a derivative of C75 that 
does not activate CPT-1 [11]. EGCG as a clinical FASN 
inhibitor is challenged by its low potency, bioavailability, 
serum stability and specificity, which is due to its off-target 
effects (inhibition of several kinases and topoisomerases) 
(reviewed in [12]). A clinical application of orlistat will 
require novel formulations, because it is poorly soluble 
and has an extremely low oral bioavailability [13]. TCS is 
an FDA-approved topical broad-spectrum antibiotic that 
inhibits type II enoyl reductase in bacteria [14] and has 
been in use for more than 30 years in personal hygiene 
products. TCS strongly binds to bacterial type II enoyl 
reductases with affinities in the low picomolar range [15]. 
Although bacterial and human FASN share very little 
sequence homology, TCS was found a decade ago to also 
inhibit the enoyl reductase partial activity of human FASN 
and to block growth of the breast cancer cell lines MCF-
7 and SKBr-3 at concentrations in the low micromolar 
range [8]. Since then, TCS-induced cytotoxicity in 
cancer cells has been reported for the retinoblastoma 
Y79 cell line, the epithelial carcinoma KB cell line [16] 
and the choriocarcinoma JEG-3 cell line [17], whereas 
similar concentrations of TCS were not cytotoxic to 
non-malignant cell lines derived from fibroblasts (3T3) 
or Müller glia (MIOM1) [16, 18]. Moreover, it has been 
demonstrated in a rat model of mammary carcinogenesis 
that TCS-mediated inhibition of FASN significantly 
reduced tumor incidence and tumor numbers per animal, 
with only minor effects on body weight and no effects on 
food intake [19]. Similarly, treatment of male rats for 60 
days with a daily dose between 5-20 mg/kg TCS did not 
induce significant changes in body weight at any of the 
test doses [20]. The lack of any significant weight loss 
strongly suggests that TCS does not share the side-effects 
of appetite suppression, CPT-1 activation, and increased 
FA β-oxidation that impeded the development of cerulenin 
and C75 into clinical FASN inhibitors.
The fact that PCa is the most frequently diagnosed 
malignancy in men and the second leading cause of male 
cancer death in industrialized countries [21] highlights 
the need for alternative therapeutic strategies to manage 
this devastating disease. Our interest to evaluate the 
FASN inhibitor TCS as a potential chemotherapeutic for 
the treatment of PCa was supported by previous findings 
that TCS showed minimal toxicity in rats, dogs and 
baboons when treated daily over several months [22] and 
that knockdown or pharmacological inhibition of FASN 
with C75 induced cell death of PCa cells in vitro and a 
reduction in tumor volume in vivo (reviewed in [4]). Here, 
we tested TCS for the first time in various PCa cell lines 
and compared its cytotoxic potency and phenotypic effects 
on cell morphology, cell cycle, cellular lipid levels, and 
expression and regulation of key enzymes involved in 
energy homeostasis and FA synthesis to the well-known 
FASN inhibitors C75 and orlistat.
RESULTS
Triclosan is cytotoxic in prostate cancer cells
In order to evaluate the effect of the FASN inhibitor 
triclosan (TCS) on the growth of the PCa cell line LNCaP 
and to compare its activity to other FASN inhibitors, we 
treated cells with TCS (2.5-20 M), C75 (5-50 µM) or 
orlistat (10-80 µM) and measured cell confluence by live 
imaging for 96 hours (Fig. 1A). In addition, we included 
TOFA (5-40 µM) in this analysis, which is an inhibitor of 
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Figure 1: Inhibition of FASN by TCS causes cytotoxicity in PCa cells. (A) Proliferation as a function of cell confluence. LNCaP 
cells were treated with control (DMSO) or the indicated concentrations of inhibitors of de novo FA synthesis, and confluence was measured 
every 2 h for 96 h on an IncuCyte FLR system (left panel). IC50 values for treatment of LNCaP cells for 48 h were calculated by non-linear 
regression analysis (n=3 ±SD, middle panel). The structures of the lipogenic inhibitors are shown (right panel). (B) Representative images 
of A after 24 h of treatment with control (DMSO) or inhibitors (TCS 7.5 µM, C75 20 µM, orlistat 30 µM and TOFA 20 µM). (C) IC50 
values for the indicated time points were calculated from the data in A (n=3 ±SD). (D) Western blot analysis of key lipogenic and energy 
sensing enzymes. LNCaP cells were treated for 24 h with control (DMSO) or the indicated inhibitors (TCS 10 µM, C75 20 µM, orlistat 20 
µM and TOFA 10 µM), and protein lysates were probed with antibodies directed against the indicated proteins. As controls, LNCaP cells 
were treated with the AMPK activators metformin (2 mM) and AICAR (0.5 mM). For quantification, total protein levels were normalized 
relative to loading control (eIF2α). The level of protein phosphorylation was calculated relative to the normalized total amount of the 
respective protein. For better clarity, irrelevant lanes were removed from the image as indicated by the gaps. (E) LNCaP cells were treated 
with control (DMSO), 10 µM TCS or 20 µM C75 for the indicated times, and FASN expression was analyzed as in D. (F) Cytotoxicity of 
TCS and orlistat is mediated by FA starvation. LNCaP cells were treated with control (DMSO), 7.5 µM TCS, 40 µM C75, 10 µM orlistat, 5 
µM palmitate (PA), or a combination of FASN inhibitor with PA (TCS+PA, C75+PA and orlistat+PA), and proliferation was measured for 
96 h as described in A. (G) Representative images of F after 24 h of incubation.
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acetyl-CoA carboxylase (ACC), the rate-limiting enzyme 
of de novo FA synthesis which converts acetyl-CoA into 
malonyl-CoA [23]. As shown in Figure 1A, all inhibitors 
were cytotoxic to LNCaP cells, and cell death was 
preceded by loss of cell-cell contacts, cell shrinkage, and 
membrane blebbing which are typical signs of apoptosis 
(data not shown). Yet, the timing of growth inhibition and 
cell death was different between the inhibitors, as indicated 
by their distinct growth profiles. While LNCaP cells 
treated with 40 µM of C75, orlistat or TOFA continued to 
grow between 20-36 h at a similar rate as control before 
their growth was negatively impacted by the inhibitors, 
cells treated with 10 µM TCS showed an immediate 
growth inhibitory effect. Kinetic analysis revealed an 
IC50 of 6.9 µM for TCS, 35.4 µM for C75, 23.5 µM for 
orlistat, and 7.5 M for TOFA (Table 1) after treatment of 
LNCaP cells for 48 h. Measurement of metabolic activity 
/ viability of LNCaP cells treated for 48 h by Alamar Blue 
assay revealed similar IC50 values (Table 1). Inspection 
of the images from the time-lapse microscopy (Fig. 1A) 
revealed that TCS induced cell morphology changes in 
LNCaP cells after 24 h which were similar to cells treated 
with orlistat or TOFA, where cells were flat and enlarged 
and highly granular. This phenotype was very similar to 
the morphological changes induced by TCS in MCF-7 
breast cancer cells [8]. In contrast, C75 caused cells to 
round up with shortened processes.
Analysis of the cell confluence-derived IC50 values 
at different time points revealed that TCS and TOFA 
reached maximum potency in growth inhibition as early as 
6 h post treatment, which remained relatively unchanged 
over the 96 h incubation period (Fig. 1C). In contrast, C75 
reached maximum potency (IC50=16.9 µM) after 72 h of 
incubation, a two-fold increase relative to the IC50 at 6 h 
(33.6 µM). A similar time-dependent increase of potency 
was also observed with orlistat (data not shown).
FASN inhibition by TCS was also cytotoxic in 
the PCa cell lines C4-2B (a castrate-resistent LNCaP 
derivative), LAPC4, 22RV1 and the metastatic PCa cell 
line PC-3 (Table 2). While TCS possessed similar IC50 
values (4.5 µM to 7.8 µM) in the different PCa cell lines, 
the potency of C75 varied by more than four-fold between 
cell lines (8.3 µM to 35.4 µM). Interestingly, the non-
malignant prostate cell lines RWPE-1, BPH-1 and WPMY-
1 also displayed increased sensitivity to TCS and C75 
(Table 2) and orlistat and TOFA (data not shown) when 
compared to non-malignant 3T3 fibroblasts. Notably, 
FASN is mainly expressed in adult hormone-sensitive cells 
like prostate cells or in cells with high lipid metabolism 
[24]. Consistent with our findings, concentrations of up 
to 100 µM TCS or C75 showed no cytotoxic effects in the 
non-malignant fibroblast cell line 3T3-L1 [18].
Previous work has shown that pharmacological 
inhibition of FASN with C93, a C75 derivative, activates 
AMP-activated protein kinase (AMPK) in SKOV3 human 
ovarian cancer cells [11]. AMPK acts as a metabolic master 
switch with a critical role in sensing cellular energy levels 
and metabolic stress stimuli (reviewed in [25]). AMPK 
activation through phosphorylation inhibits de novo FA 
biosynthesis through phosphorylation and repression 
of the lipogenic transcription factor, SREBP1, which 
regulates the expression of FASN [11], androgen receptor 
expression and PCa progression [26, 27]. In addition, 
activated AMPK directly phosphorylates ACC, thereby 
IncuCyte Alamar Blue
compound IC50 [µM] 95% CI [µM] IC50 [µM] 95% CI [µM]
TCS 6.9 6.4-7.4 6.6 6.3-6.9
C75 35.4 32.1-39.1 43.6 39.0-48.6
orlistat 11.8 8.0-17.4 26.4 23.2-30.0
TOFA 7.0 5.7-8.6 13.8 10.4-18.4
TCS C75
Cell line IC50 [µM] 95% CI [µM] IC50 [µM] 95% CI [µM]
LNCaP 6.9 6.4-7.4 35.4 32.1-39.1
C4-2B 5.9 5.4-6.0 32.1 29.9-34.4
LAPC4 7.8 5.3-11.5 28.3 23.2-32.6
22RV1 4.5 4.0-5.2 9.1 7.8-10.6
PC-3 6.8 6.2-7.4 8.3 7.9-8.8
RWPE-1 0.74 0.66-0.76 1.6 1.4-1.8
BPH-1 10.3 9.6-11.0 15.2 14.0-16.5
WPMY-1 12.9 12.2-13.5 28.2 27.4-29.0
NIH3T3 62.3 58.8-66.1 60.0 56.4-63.8
Table 1: IC50 in LNCaP cells measured by IncuCyte and Alamar Blue
Table 2: IC50 in malignant and non-malignant cell lines measured by IncuCyte and Alamar 
Blue
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inhibiting malonyl-CoA synthesis, the rate-limiting step of 
de novo FA synthesis. Reduced malonyl-CoA levels in turn 
activate mitochondrial FA β-oxidation through relieved 
inhibition of carnitine O-palmitoyltransferase 1 (CPT-1) 
[28]. Hence, we investigated the effects of the lipogenic 
inhibitors TCS, C75, orlistat and TOFA on protein 
expression and phosphorylation levels of FASN, ACC and 
AMPK by Western blot analysis (Figs. 1D and 1E). As 
positive controls, we treated LNCaP cells with metformin 
or 5-aminoimidazole-4-carboxamide 1-β-D-ribofuranoside 
(AICAR) which lead to phosphorylation and activation 
of AMPK (reviewed in [25]). As shown in Figure 1D, 
the four lipogenic inhibitors TCS (1.8-fold), C75 (2.3-
fold), orlistat (2.8-fold) and TOFA (2.9-fold) caused an 
increase in AMPK phosphorylation which was similar to 
metformin (2.2-fold) and AICAR (2.0-fold). Consistent 
with increased AMPK activity, phosphorylation of ACC 
(P-ACC) was increased by all three FASN inhibitors. 
Interestingly, like metformin and AICAR, TCS and orlistat 
decreased FASN protein levels. Yet, FASN expression 
remained largely unchanged by C75 and TOFA. Western 
Blot analysis of a time course experiment revealed that 
TCS caused a decrease in FASN protein by 2.5-fold after 
72 h, while C75 increased FASN protein by 1.5-fold (Fig. 
1E). Taken together, inhibition of de novo lipogenesis 
through pharmacological targeting of ACC or FASN 
increased the phosphorylation of AMPK and its target 
ACC. Importantly, the FASN inhibitors TCS, C75 and 
orlistat, which target different partial catalytic activities of 
FASN, had distinct effects on its protein levels.
Next we investigated whether the cytotoxic 
effect of TCS, C75 and orlistat was caused through end 
product starvation of palmitate. We performed a rescue 
experiment where we supplemented TCS-treated LNCaP 
cells with exogenous palmitate and measured growth in 
real time (Fig. 1F). When compared to control, addition 
of palmitate did not affect growth of LNCaP cells. 
However, supplementation with exogenous palmitate 
rescued the profound growth inhibition produced by TCS 
(Fig. 1F). Similarly, exogenous PA recued the growth 
inhibition induced by orlistat (Fig. 1F), which has been 
reported previously in PC-3 cells [29]. Furthermore, TCS-
treated LNCaP cells did not display the above described 
morphological phenotype (flat, enlarged and highly 
granular cells) when co-treated with exogenous palmitate 
(Fig. 1G). These results indicated that the anti-proliferative 
and morphological effects of TCS were a result of end 
product starvation which was mediated through FASN 
inhibition. In contrast, C75-induced growth inhibition 
of LNCaP cells could not be rescued by palmitate (Fig. 
1F). This observation is consistent with a previous study 
[30], which suggested that increased malonyl-CoA levels 
might be the major cause for cytotoxicity of C75 [31]. 
Altogether, these findings demonstrate that the FASN 
inhibitor TCS is a potent cytotoxic compound in PCa 
cells. Furthermore, these results highlight that inhibition of 
different partial catalytic activities of FASN with different 
inhibitors can produce distinct phenotypes regarding cell 
morphology, expression levels of FASN and mechanism 
of growth inhibition.
Triclosan, C75 and orlistat have different effects 
on the expression of lipogenic genes
The above observed changes to FASN protein 
levels by the inihibitors raised the possibility that these 
effects were caused through transcriptional changes 
via SREBP1. In addition, we investigated key genes 
of FA synthesis (ACC and FASN) and FA metabolism 
like FA uptake and transport (SLC27A1 and ACBP), 
FA conversion (HSL/LIPE, ACSL5 and FADS-2), FA 
β-oxidation (CPT-1), and arachidonic acid metabolism 
(PLA2G6 and PTGS1) by quantitative real-time PCR 
(Figs. 2A-2C). As shown in Figure 2A, TCS, C75 and 
orlistat did not affect the mRNA expression of SREBP1 
and ACC in LNCaP cells (Fig. 2A). In contrast, TOFA led 
to a significant upregulation of SREBP1 mRNA levels and 
decrease in ACC expression (Fig 2A). More importantly, 
TCS significantly reduced the gene expression of FASN, 
whereas C75, orlistat and TOFA caused a significant 
increase (Fig. 2A). In addition, the lipogenic inhibitors 
displayed distinct effects on the transcript levels of FA 
transporters SLC27A1 and ACBP, hormone-sensitive 
lipase HSL/LIPE which hydrolyzes stored triglycerides to 
free FAs, acyl-CoA synthase ACSL5, and FA desaturase 
FADS-2 (Fig. 2B). We observed that both orlistat and 
TOFA significantly decreased the expression of carnitine 
palmitoyltransferase (CPT-1), which controls the rate-
limiting step of FA β-oxidation. Of note was also the 
opposite regulation of phospholipase PLA2G6 expression 
by TCS compared to C75, orlistat and TOFA. PLA2G6 
has been shown to play a role in the release of FA and 
arachidonic acid from phospholipids [32]. Consistent with 
a potential effect of orlistat and TOFA on the arachidonic 
acid pathway, both inhibitors caused a strong decrease in 
the expression of PTGS1, which catalyzes the conversion 
of arachidonic acid into prostanglandin [33]. Acetyl-CoA, 
the building block of FA synthesis, is also a substrate 
of the mevalonate pathway, which is important for the 
synthesis of cholesterol, sterols and other isoprenoids. The 
FA and cholesterol synthesis pathways are coordinately 
regulated by a feedback system mediated by SREBP1 
and SREBP2 [34]. SREBP2 regulates the expression of 
hydroxy-methyl-glutaryl-CoA synthase (HMGCS) and 
hydroxy-methyl-glutaryl-CoA reductase (HMGCR), 
two key enzymes of cholesterol synthesis. In addition, 
previous work has shown that C75 and TOFA inhibited 
sterol synthesis in primary hepatocytes [35]. Hence, we 
tested if FA synthesis inhibition affected the expression 
of SREBP2, HMGCS, and HMGCR by qRT-PCR (Fig. 
2C). In contrast to TCS and C75, orlistat and TOFA caused 
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a significant up-regulation in the expression of SREBP2, 
HMGCS and HMGCR, suggesting that the latter two 
inhbitors stimulate cholesterol synthesis in LNCaP cells 
through a feedback mechanism. In summary, inhibition 
of de novo FA synthesis with different ACC and FASN 
inhibitors activates distinct transcriptional responses of 
genes involved FA and cholesterol metabolism.
Triclosan causes a G0/G1 cell cycle arrest and 
induces apoptosis in PCa cells
We next performed DNA content analysis by 
FACS to measure the effect of different concentrations 
of TCS, C75 and orlistat on the cell cycle distribution 
of asynchronously growing LNCaP cells after 48 h of 
Figure 2: Inhibition of FA synthesis causes distinct effects on the expression of key genes involved in FA and cholesterol 
metabolism. (A) The expression of SREBP1, ACC and FASN was analyzed by qRT-PCR after treatment of LNCaP cells with TCS (5 
µM), C75 (20 µM), orlistat (20 µM), and TOFA (10 µM) for 48 h (n=3, mean±SD, *p<0.05, **p<0.01, ***<0.001). (B) The indicated genes 
involved in various aspects of FA metabolism were analyzed as in A. (C) Effect of FA synthesis inhbitiors on the expression of key enzymes 
of cholesterol synthesis. SREBP2, HMGCS and HMGCR expression was analyzed as in A.
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Figure 3: TCS causes G0/G1 cell cycle arrest and induces apoptosis in PCa cells. (A) LNCaP cells were treated with control 
(DMSO), 10 µM TCS, 40 µM C75 or 40 µM orlistat for 48 h, and cell cycle distribution was analyzed by flow cytometry and quantitated 
with ModFit LT. (B) PC-3 cells were treated with the indicated concentrations of TCS for 48 h and analyzed as in A. The results are 
representative of three independent experiments. (C) LNCaP cells were treated for 48 h with the indicated concentrations of TCS analyzed 
by flow cytometry. The percentage of dead cells with hypodiploid subG1 DNA content was quantitated with ModFit LT (n=3, mean±SD, 
*p<0.05, **p<0.01). (D) LNCaP cells were treated with 20 µM TCS for the indicated times and analyzed as in C. (E) LNCaP were treated 
with the indicated concentrations of TCS for 48 h, and apoptosis was analyzed by co-staining with Annexin V-FITC and PI. Early apoptotic 
cells (Annexin V-positive and PI-negative cells) were quantitated by flow cytometry (n=3, mean±SD, *p<0.05, **p<0.01). (F) LNCaP 
cells were treated as in E, and PARP cleavage was detected by immunoblotting. (G) FASN expression and lipogenesis were stimulated 
by treating androgen-deprived LNCaP cells (black bars) with 10 nM DHT (grey bars) or 5% FBS (white bars) prior incubation with the 
indicated concentrations of TCS for 48 h. The number of apoptotic cells was quantitated as in C. (H) Activation of AMPK decreases FASN 
expression and cellular lipid levels. Western blot analysis of FASN expression in LNCaP cells after treatment with 2 mM metformin for 
48 h. As a loading control, protein levels of eIF2 were determined. Cellular lipid levels of LNCaP cells treated with 2 mM metformin 
or 0.5 mM AICAR for 48 h were measured by Nile Red staining and flow cytometry. LNCaP cells were incubated with the indicated 
concentrations of TCS for 48 h in the absence (white bars) or presence of metformin (black bars). Cell death was measured as in C (n=3, 
mean±SD, *p<0.05, **p<0.01). (I) LNCaP cells were treated with 5 µM TCS, 1-2 mM metformin or a combination of both compounds, and 
cell confluence was measured every 2 h for 72 h (top panel). The co-treatment of LNCaP cells was repeated with 7.5 µM TCS and 0.25-0.5 
mM AICAR for 96 h (bottom panel).
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treatment. Similar to previous studies in RKO colon 
cancer cells [36] and A-375 melanoma cells [37], C75 
increased the number of LNCaP cells in S phase and G2/M 
of the cell cycle (Fig. 3A). We observed similar results in 
PC-3 and LAPC4 cells (data not shown). Importantly, Ho 
et al. showed that the G2/M arrest of A-375 melanoma 
cells generated by C75 preceded induction of apoptosis 
and DNA fragmentation [37], suggesting that C75 is 
cytotoxic in proliferating cells. Consistent with this, C75 
was more potent in fast growing PCa cell lines (PC-3 and 
22RV1) when compared to slow growing LNCaP cells 
(Table 2). Unlike C75, TCS (10 µM) and orlistat (40 µM) 
led to an increase in the number of cells in G0/G1 and, 
concomitantly, a reduction of S phase and G2/M cells 
(Fig. 3A), suggesting a cell cycle arrest in G0/G1, which 
was previously reported for orlistat in the breast cancer 
cell line MDA-MB-435 [38]. Consistent with the above 
findings in LNCaP cells, TCS also caused a G0/G1 cell 
cycle arrest in PC3 (Fig. 3B) and 22RV1 cells (data not 
shown). 
Compared to the control, treatment with 20 µM 
TCS caused a 12-fold increase in the number of LNCaP 
cells in the hypodiploid subG1 peak, which is indicative 
of DNA fragmentation and cell death (Fig. 3A). For 
comparison, 30 µM C75 and 40 µM orlistat increased 
the number of cells in subG1 by six-fold and 11-fold, 
respectively (Fig. 3A). Further subG1 analysis of titration 
(Fig. 3C) and time course experiments with LNCaP 
cells (Fig. 3D) showed that TCS induced cell death in a 
concentration- and time-dependent manner. Similar results 
were observed in PC-3 cells (data not shown). Importantly, 
FACS analysis of the apoptosis marker phosphatidylserine 
with Annexin V confirmed that TCS induced cell death 
through apoptosis in a concentration-dependent manner 
in LNCaP (Fig. 3E) and PC-3 cells (data not shown). 
Furthermore, immunoblotting with poly(ADP-ribose) 
polymerase (PARP) antibody showed that TCS caused 
PARP cleavage in LNCaP cells (Fig. 3F). Together, these 
results demonstrate that TCS causes a G0/G1 cell cycle 
arrest and induces apoptosis in PCa cells.
Consistent with the above findings that TCS caused 
cytotoxicity predominantly through end product starvation 
(Fig. 1F), androgen deprivation (Fig. 3G) or inhibition 
of androgen signalling with the androgen receptor 
antagonist bicalutamide (data not shown), which reduces 
expression of the androgen receptor-regulated FASN 
gene and lipogenesis [39, 40], increased the sensitivity of 
LNCaP cells to TCS, as shown by a significant increase 
in dead cells in the hypodiploid subG1 population when 
compared to cells grown in the presence of the androgen 
dihydrotestosterone (DHT) or 5% fetal calf serum 
(Fig. 3G). Similar results were observed in androgen-
sensitive 22RV1 cells (results not shown). Similarly, co-
treatment with the AMP-activated protein kinase (AMPK) 
activator metformin, which leads to a robust reduction of 
FASN expression and cellular lipid levels (Fig. 3H) via 
suppression of the lipogenic transcription factor SREBP1 
[28], enhanced the cytotoxic effect of TCS in LNCaP 
(Fig. 3H) and 22RV1 cells (data not shown), as indicated 
by a substantial increase in dead cells (hypodiploid 
subG1 population) when compared to TCS or metformin 
treatment alone. Consistent with this, real-time live cell 
imaging demonstrated that co-treatment of LNCaP cells 
with TCS and the AMPK agonists metformin or AICAR 
substantially enhanced the cytotoxic effect of TCS when 
compared to the individual treatments (Fig. 3I). Taken 
together, these results indicate that the levels of FASN 
expression and lipogenesis are strongly correlated with 
sensitivity of PCa cells to TCS.
Triclosan reduces the lipid content of LNCaP cells
To evaluate the effect of FASN inhibition by TCS 
or C75 on the cellular lipid content, we stained LNCaP 
cells with the lipophilic fluorescent dye, Nile Red. 
The fluorescence intensity of Nile Red-stained cells is 
linearly correlated with the lipid content [41]. Nile Red 
displays different emission maxima, depending on the 
hydrophobicity of the bound lipids [42]. For example, 
when excited at 485 nm, Nile Red-stained neutral lipids 
like triacylglycerols and cholesterol esters, which are 
the main contents of lipid droplets, fluoresce with an 
emission maximum of ~520 nm, while polar lipids like 
phosphatidylcholine, phosphatidylethanolamine and 
phosphatidylserine, which are the main constituents of 
lipid bilayers, have an emission maximum of ~620 nm. 
As shown in Figure 4A, fluorescence microscopy revealed 
that treatment of LNCaP cells with 10 µM TCS visibly 
reduced the staining of neutral and polar lipids when 
compared to control or cells treated with 30 µM C75 (Fig. 
4A). Quantitative analysis of Nile Red-stained lipids in 
LNCaP cells indicated that increasing concentrations 
of TCS lowered the neutral and polar lipid content 
by up to two-fold (Fig. 4B). This was in stark contrast 
to the biphasic effect seen with C75, where increasing 
concentrations from 5-30 µM caused a steady rise of the 
lipid content, while C75 at 40 M reversed this stimulatory 
effect. We repeated the measurement of cellular lipids with 
LNCaP cells in which FASN expression and neutral lipid 
levels were markedly upregulated through stimulation 
of lipogenesis with the synthetic androgen mibolerone 
[39, 40] prior to the addition of TCS (Fig. 4C). When 
compared to control, androgen treatment increased the 
neutral lipid content by almost 8-fold. Incubation with 
10-20 µM TCS caused a decline in neutral lipids of up 
to 2.5-fold, while only a modest reduction in the lipid 
content was detected when treated with 40 µM C75 (Fig 
4C). Taken together, these results demonstrated that the 
FASN inhibitor TCS reduced the lipid content of LNCaP 
cells in a concentration-dependent manner.
Oncotarget11www.impactjournals.com/oncotarget
The hydroxyl group of triclosan is critical for its 
cytotoxicity
We next tested the commercially available triclosan 
derivative, methyl triclosan (TCSm, 2), in which the 
hydroxyl group of the phenol is replaced by a methyl ether 
group (Table 3). As shown in Figure 5A, FACS analysis 
of the hypodiploid subG1 cell population revealed that 
equimolar concentrations of TCSm (2) failed to induce 
cell death in LNCaP cells after 48 h of treatment when 
compared to TCS. We observed similar results in the 
22RV1 cell line (results not shown). Furthermore, live 
cell analysis of cell confluence (IncuCyte) demonstrated 
that TCSm (2) reduced cell growth of LNCaP cells at 
concentrations higher than 20 µM, but no cytotoxicity 
was detected at concentrations of up to 80 µM (Fig 5B). 
Similar results were obtained by Alamar Blue assay (Table 
Figure 4: Triclosan reduces the lipid levels of LNCaP cells. (A) LNCaP cells treated with 10 µM TCS or 30 µM C75 for 48 h. 
Neutral (yellow) and polar lipids (red) were labelled with Nile Red and visualized by fluorescence microscopy. DNA was counterstained 
with DAPI (blue). (B) LNCaP cells were grown in 5% FBS before treatment with the indicated concentrations of TCS (black bars) or C75 
(gray bars) for 48 h. After fixation, cellular lipids were stained with Nile Red, and fluorescence of neutral lipids was measured in a plate 
reader (n=3 ±SD, *p<0.05, **p<0.01). (C) FASN expression and lipogenesis were stimulated by treating androgen-deprived LNCaP cells 
(white bar) with 1 nM mibolerone (light gray bar) for 72 h prior incubation with the indicated concentrations of TCS (black bars) or C75 
(dark gray bars) for 48 h. Samples were processed and measured as in B.
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3). Kinetic analysis of the IncuCyte and Alamar Blue data 
for TCSm treatment of LNCaP cells for 48 h with revealed 
an IC50 of 52.6 µM and 60.8 µM (Table 3), respectively, 
representing an 8 to 9-fold reduction in potency when 
compared to TCS (6.9 µM and 6.6 µM). We also noticed 
that TCSm did not induce the above described changes to 
cell morphology, e.g. flat and enlarged cells with increased 
granularity (results not shown), and 20 µM TCSm did not 
reduce the neutral and polar lipid content of LNCaP cells 
(Table 3). These results suggested that the hydroxyl group 
of triclosan may be critical for its potency as a FASN 
inhibitor, and prompted us to generate five derivatives for 
preliminary structure-activity relationship studies (Table 
3). The IC50 of the TCS analogs were determined in 
LNCaP cells by live cell imaging (IncuCyte) and Alamar 
Blue assay, and cellular lipid levels were measured by 
Nile Red staining (Table 3). All analogs but TCS15 (3) 
showed substantial losses in cytotoxic potency (Fig. 
5C) and the ability to reduce cellular lipid levels (Table 
3), respectively. Interestingly, LNCaP cells displayed a 
biphasic dose response profile when treated with 10-20 µM 
TCS15 (Fig 5D), where, unlike the parent compound (Fig. 
1A), cytotoxicity was observed with a delay of 24 h post 
treatment. We suggest that the inhibitory effect of TCS15 
can be explained by hydrolysis of the phenolic acetate 
to release the parent compound in the biological system. 
Changes in alcohol pKa and spacing substantially reduced 
activity, as shown for analog TCS57 (6), which bears a 







TCS (1) 6.9 6.6 0.40 0.19
TCSm (2) 52.5 60.8 0.97 1.09
TCS11 (5) 44.8 50.0 0.70 1.06
TCS15 (3) 9.3 9.5 0.56 0.60
TCS57 (6) 34.5 49.3 0.90 0.81
TCS79 (7) 44.8 50.1 1.29 1.13
TCS79n2 (8) 56.3 54.7 1.10 1.03
*Lipid content relative to DMSO at 20 µM for 48 h
Table 3: Structure-function relationship analysis of TCS analogs: Cytotoxic potency and relative 
lipid levels
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Figure 5: The hydroxyl group of triclosan is critical for its cytotoxic activity. (A) LNCaP cells were treated for 48 h with 
control (DMSO) or increasing concentrations of TCS (black bars) or its derivative TCSm (gray bars). Samples were analyzed by flow 
cytometry, and the percentage of apoptotic cells with hypodiploid subG1 DNA content was quantitated with ModFit LT. (B) LNCaP cells 
were treated with control (DMSO) or the indicated concentrations of TCSm, and confluence was measured every 2 h for 96 h (n=3 ±SD). 
(C) LNCaP cells were treated with increasing concentrations of the indicated TCS analogs and monitored by live cell imaging as described 
in B. Non-linear regression analysis of the dose response for 48 h is shown. (D) LNCaP cells were treated with control (DMSO) or the 
indicated concentrations of TCS15, and growth was measured as described in B (n=3 ±SD). (E) Western blot analysis of key lipogenic 
and energy sensing enzymes. LNCaP cells were treated for 24 h with control (DMSO) or 10 µM of the indicated TCS analogs, and protein 
lysates were probed with antibodies directed against the indicated proteins. For quantification, total protein levels were normalized relative 
to loading control (eIF2α). The level of protein phosphorylation was calculated relative to the normalized total protein amount.
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chain-extended benzylic alcohol in place of the parent 
phenol. Similarly, compounds TCS79 (7) and TCS79n2 
(8), which bear chain-extended ester and carboxylic acid 
functionality, respectively, did not maintain the inhibitory 
activity of TCS. Analogs TCSm (2) and TCS11 (5), which 
lack alcohol functionality showed very limited inhibitory 
activity. Together, these results strongly suggest that the 
activity of TCS is dependent on alcohol functionality of 
the parent phenol.
As shown above, inhibition of FASN by TCS 
increased the levels of phosphorylated AMPK and ACC 
and decreased FASN protein levels (Figs. 1D and 1E). To 
determine if these molecular effects were correlated with 
the cytotoxic effect of the TCS analogs, we treated LNCaP 
cells for 24 h with 10 µM of the TCS analogs and analyzed 
FASN, ACC and AMPK expression by Western blot 
analysis (Fig. 5E). Notably, among the five analogs, only 
TCS (Fig. 1A) and TCS15 (3) (Figs. 5C and 5D) inhibited 
growth of LNCaP cells at this concentration. As shown 
in Figure 5E, all TCS analogs caused a similar increase 
in AMPK phosphorylation (1.5 to 2.1-fold), whereas 
phosphorylation of ACC was increased the most by TCS 
(3.9-fold) followed by TCS15 (2.7-fold). Similarly, FASN 
expression was decreased the most by TCS (-1.8-fold) and 
TCS15 (-1.4-fold), while the less cytotoxic analogs caused 
only a modest change in FASN levels (-1.2 to 1.2-fold). 
Taken together, these results suggest that TCS-induced 
cytotoxicity is linked to a reduction in FASN protein 
levels but does not correlate with the level of AMPK 
phosphorylation. In summary, these results demonstrated 
that the hydroxyl group is critical for the activity of TCS 
in inhibiting cancer cell growth and reducing cellular lipid 
levels and FASN expression.
DISCUSSION
TCS has U.S. Food and Drug Administration (FDA) 
approval as a bactericide in personal hygiene products 
(toothpaste, mouth rinse, handwash, soaps, deodorant) 
and has been used since 1968. TCS has an established 
safety profile, with minimal toxicity in rats, dogs, baboons 
and humans, no significant weight loss is associated with 
TCS treatment, and TCS is not a genotoxic or mutagenic 
compound. TCS has excellent oral bioavailability and 
stability in plasma (reviewed in [43]). Promising results 
have shown previously that FASN inhibition by TCS 
showed chemo-preventative activity in a rat mammary 
carcinogenesis model [19]. In this study we evaluated 
TCS, which inhibits the enoyl reductase domain of FASN 
[8], as a repurposed drug against PCa cells and compared 
its activity to C75 and orlistat, two well-known FASN 
inhibitors whose clinical development are impeded 
by various pharmacological limitations (reviewed in 
[44]). Orlistat, a U.S. FDA-approved drug designed for 
obesity, inhibits pancreatic lipase, thereby preventing 
the absorption of free FAs from the diet in the intestine. 
Orlistat is also an irreversible inhibitor of the thioesterase 
activity of FASN and decreases cell viability of PCa cells 
by inducing apoptosis [29]. Its potential application for 
cancer chemotherapy is limited by its poor solubility 
and very low level of oral bioavailability (reviewed in 
[44]). C75 is a synthetic analog of cerulenin and lacks the 
unstable, highly reactive epoxy group [9]. FASN inhibition 
by C75 induces apoptosis [45] and showed significant 
antitumor activity with little adverse effects on normal 
proliferating tissues, such as bone marrow, intestine, 
skin, or lymphoid tissue [9]. However, studies in mice 
revealed that C75 causes strong appetite suppression and 
profound weight loss through direct activation of carnitine 
O-palmitoyltransferase (CPT-1), thereby increasing FA 
β-oxidation [10]. With regards to mechanism of action, 
C75 is a unique FASN inhibitor since it targets the first 
reaction step which is catalyzed by the β-ketoacyl synthase 
partial activity, as well as inactivates the TCS-targeted 
enoyl reductase and orlistat-targeted thioesterase partial 
activities with similar rates [5].
Like C75 and orlistat [29, 45], FASN inhibition 
by TCS ultimately caused cell death of LNCaP cells via 
apoptosis in a concentration- and time-dependent manner 
(Figs. 3A-3F). TCS was cytotoxic in five different PCa 
cell lines with similar IC50s in the low micromolar 
range (4.5-7.8 µM). Early structure-function relationship 
analysis with a panel of seven TCS analogs suggested that 
alcohol functionality of the parent phenol is critical for 
cytotoxic potency (Fig. 5 and Table 3). In comparison, 
C75 displayed cytotoxic potency that varied by more than 
four-fold between PCa cell lines (8.3-35.4 µM, Table 2) 
and appeared to be correlated with the proliferation rate 
/ number of cells in S phase (data not shown). Indeed, 
previous work has shown that C75 induces apoptosis of 
MCF7 and A-375 during S phase [37], suggesting that 
C75 is more potent in rapidly proliferating cancer cells. 
Similar to previous reports [18], we found that TCS and 
C75 were non-cytotoxic at up to 60 µM in non-malignant 
NIH3T3 fibroblasts. Yet, our analysis showed considerable 
cytotoxicity of TCS and C75 in the non-malignant 
prostate cell lines BPH-1, RWPE-1 and WPMY-1, with 
IC50s ranging between 0.74 M and 28.2 µM (Table 2). 
A recent study described a similar observation, showing 
that RWPE-1 cells were more sensitive to FASN inhibition 
by siRNA or C75 than the malignant cell lines LNCaP, 
DU145 or PC-3 [46]. Furthermore, TCS has been shown 
to induce degeneration and atrophy of prostatic tissue 
in rats after treatment for 60 days with a daily dose of 
20 mg/kg [20]. Taken together, our observations suggest 
that cells of prostatic origin are particularly sensitive 
to FASN inhibition. We found no correlation between 
FASN inhibitor sensitivity and the status of the androgen 
receptor, PTEN, or p53 in the cell lines tested (results not 
shown).
Real-time monitoring of FASN inhibitor cytotoxicity 
by IncuCyte technology based on cell confluence provided 
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valuable kinetic information about potency, growth 
inhibition and cell death (Fig. 1A). These observations 
were validated by Alamar Blue assay which measures 
cell viability based on metabolic activity (Table 1). 
Interestingly, inhibition of the rate-limiting enzyme of 
de novo FA synthesis, ACC, with TOFA or FASN with 
TCS reached maximum potency in LNCaP cells as early 
as 6 h after treatment commenced and remained relatively 
unchanged over the entire incubation period (Fig. 1C). 
This is in agreement with a significant rise in cell death 
of LNCaP cells when treated for >6 h with TCS (Fig. 3D). 
In contrast, the potency of C75 (Fig. 1C) and orlistat (data 
not shown) to inhibit growth of LNCaP cells changed 
by two-fold over the treatment period and required 
up to 72 h to reach maximum potency. Importantly, 
this analysis demonstrated that there were substantial 
differences between the four inhibitors of de novo FA 
synthesis (TOFA, TCS, C75 and orlistat) with regards to 
growth profile and timing of growth inhibition at IC50 
(Fig. 1A) and time-dependent maximum potency (Fig 
1C), suggesting that they induced cytotoxicity through 
different mechanisms, e.g., end product starvation or 
accumulation of toxic levels of malonyl CoA substrate 
or intermediates of palmitate synthesis. Indeed, rescue 
experiments with exogenous palmitate showed that TCS- 
and orlistat-induced cytotoxicity was largely caused by 
end product starvation (Fig. 1G). This mechanism of 
cytotoxicity was previously reported for orlistat in PC-3 
cells [29]. Consistent with earlier work [30], C75-induced 
growth inhibition of LNCaP cells could not be rescued 
by palmitate (Fig. 1G), and it was suggested previously 
that accumulation of toxic levels of malonyl-CoA caused 
cytotoxicity of C75 [31]. This is a particularly interesting 
observation, given that (i) C75 inactivates three partial 
activities of FASN (β-ketoacyl synthase, enoyl reductase 
and thioesterase) with similar rates [5], (ii) inhibition 
of the enoyl reductase activity by TCS and thioesterase 
activity by orlistat cause cytotoxicity predominantly 
through end product starvation (Fig. 1G) and (iii) TCS-
mediated inhibition of the enoyl reductase activity was 
suggested to increase the concentration of the enoyl 
thiolester intermediate, which strongly resembles the 
two β-ketoacyl reductase inhibitors, CM-55 and C75 [8]. 
Hence, it will be interesting to address biochemically in 
future work how inactivation of various partial catalytic 
activities of FASN contribute to overall cytotoxicity 
through accumulation of potentially toxic metabolites.
In addition to the cause of cytotoxicity by end 
product starvation, TCS-mediated inhibition of FASN 
generated phenotypes in LNCaP cells with regards to cell 
morphology (Fig. 1B), cell cycle (Fig. 3) and expression 
of FASN protein (Fig. 1D) that resembled the effects seen 
with orlistat, which were distinctively different to C75. 
Of note was our discovery that TCS caused a significant 
reduction in FASN gene (Fig. 2) and protein expression 
(Figs. 1D and 1E) in LNCaP cells, while C75 led to an 
increase. FASN gene expression was also increased by 
orlistat and TOFA. Yet, gene expression of the lipogenic 
transcription factor SREBP1 remained unchanged by 
the FASN inhibitors TCS, C75 and orlistat, while it was 
increased two-fold by TOFA. In addition, we discovered 
that the lipogenic inhibitors caused distinct changes to the 
expression of genes involved in FA uptake and transport 
(SLC27A1 and ACBP), FA conversion and remodeling 
(HSL/LIPE, ACSL5 and FADS-2), FA β-oxidation (CPT-
1), and arachidonic acid metabolism (PLA2G6 and 
PTGS1) (Fig. 2), suggesting the activation of different 
feedback mechanisms. This was further exemplified by 
the significant upregulation of key genes of cholesterol 
synthesis (SREBP2, HMGCS and HMGCR) by orlistat 
and TOFA but not TCS and C75.
We also observed that inhibition of de novo 
FA synthesis with four different inhibitors targeting 
ACC (TOFA) and FASN (TCS, C75, orlistat) caused 
a substantial increase in AMPK phosphorylation. Yet, 
siRNA-mediated knockdown of FASN protein by 94% 
after 96 h did not change AMPK phosphorylation (data not 
shown). Furthermore, the levels of AMPK phosphorylation 
did not correlate with cytotoxic potency, FASN inhibition 
and reduction of cellular lipids, as shown by the inactive 
TCS analogs (Table 3). These observations suggest 
that AMPK phosphorylation was not directly induced 
by a reduction in de novo FA synthesis, and that other 
canonical or non-canonical pathways might be responsible 
for AMPK activation, e.g. xenobiotic or oxidative stress 
(reviewed in [25, 47]). Furthermore, while metformin- and 
AICAR-induced upregulation in AMPK phosphorylation 
caused an expected and proportional increase in ACC 
phosphorylation, we noticed that this was not the case with 
the lipogenic inhibitors (Fig. 1D).
Previous work has shown that 7.9–39.4 µM C75 
substantially reduced incorporation of [U-14C]acetate 
via inhibition of de novo synthesis into acylglycerides 
(80%) and FAs (50%) in HL60 cells without affecting 
phospholipid synthesis [9]. Interestingly, C75 caused 
a biphasic effect on total neutral and polar lipid content 
(Fig. 4), which is the sum of lipids derived from de novo 
synthesis and recycling pathways. 5-30 µM C75 increased 
the neutral lipid content of LNCaP cells, while 40 µM C75 
suppressed this stimulation to base line levels (Fig. 4B). 
Previous work in CHO-K1 cells has shown that C75-
induced cellular stress caused lipid droplet biogenesis and 
metabolic synthesis of triacylglycerol through recycling 
of structural phospholipids [48]. In contrast, TCS reduced 
cellular lipid levels in a concentration-dependent manner 
(Figs. 4B and 4C), suggesting that TCS affected the FA 
recycling pathway differently. Furthermore, preliminary 
structure-function relationship studies with seven TCS 
analogs demonstrated that the reduction of cellular 
lipid levels was correlated with cytotoxic potency and 
dependent on alcohol functionality of the parent phenol, 
respectively.
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Androgen ablation therapy (ADT) has been the 
standard treatment for metastatic PCa for decades, and 
treatment of type II diabetes with the AMPK activating 
drug metformin has been shown to improve patient 
outcomes in PCa (reviewed in [49]). Moreover, a recent 
study of the novel AMPK activator MT 63-78 provided a 
rationale for blocking lipogenesis through the combined 
targeting of AMPK and the androgen receptor in advanced 
PCa [50]. Consistent with these reports, we found that 
ADT and treatment with the AMPK activators metformin 
and AICAR, which cause a reduction of FASN gene and 
protein expression and lipogenesis, sensitized LNCaP cells 
to FASN inhibition by TCS (Figs. 2G-2I), suggesting that 
combination therapy of FASN inhibitors with ADT and/or 
AMPK activators (metformin, AICAR, MT 63-78) might 
improve the clinical outcome of PCa patients.
In this comparative study we discovered that TCS 
is a superior alternative to C75 and orlistat in inducing 
cell death of PCa cells via inhibition of FASN. Strikingly, 
inhibition of different partial catalytic activities of 
FASN generated distinct phenotypes with regards to 
cell morphology, cell cycle, total lipid content, and the 
expression of FASN and key genes of FA and cholesterol 
metabolism, highlighting the need for further studies of 
the mechanism of action of the cytotoxicity-inducing 
molecule(s), i.e. malonyl-CoA, intermediates of FA 
synthesis, depletion of palmitate. The known safety 
profile of TCS and its chemo-preventative antitumorigenic 
activity warrant further characterization of TCS in a pre-
clinical setting to address its efficacy in inhibiting PCa 
xenograft tumor growth. Thus, TCS-mediated inhibition 
of the metabolic oncogene FASN has promising potential 




phenol] (1) (Merck Calbiochem), methyl triclosan 
[5-chloro-2-(2,4-dichlorophenoxy)anisole] (2) (Sigma), 
C75 [(2R*,3S*)-Tetrahydro-4-methylene-2-octyl-5-oxo-
3-furancarboxylic acid] (Sigma, Tocris Bioscience), 
orlistat [N-formyl-L-leucine (1S)-1-[[2S,3S)-3-hexyl-
4-oxo-2-oxetanyl]methyl]dodecyl ester] (Sigma), 
AICAR [5-amino-1-β-D-ribofuranosyl-1H-imidazole-
4-carboxamide] (Sigma), TOFA [5-(Tetradecyloxy)-2-
furoic acid] (Sigma) were dissolved in DMSO, metformin 
[1,1-dimethylbiguanide hydrochloride] (Sigma) was 
dissolved in phosphate-buffered saline (PBS), Nile Red 
(Sigma) was dissolved in acetone and diluted in PBS, 
the androgens dihydrotestosterone (DHT) (Sigma), 
mibolerone (a kind gift from Dr. L. Butler) and R1881 
(Dupont) as well as palmitate (Sigma) were dissolved in 
95% ethanol (EtOH) and diluted in 20% ethanol.
Cell culture
LNCaP, C4-2B, PC-3, 22RV1, and RWPE-1 cells 
were obtained from the American Type Cell Culture 
Collection. LAPC4, BPH-1, WPMY-1, and 3T3 cells 
were kind gifts from P. J. Russell, J. Clements and J. 
Whitehead, respectively. LNCaP, C4-2B, PC-3, 22RV1, 
BPH-1, and WPMY-1 cells were maintained in phenol-
red free RPMI-1640 medium (Invitrogen) supplemented 
with 5% fetal calf serum (FBS) (Invitrogen) at 37°C in 
an atmosphere containing 5% CO2. LAPC4 cells were 
grown in Iscove’s Modified Dulbecco’s Medium (IMDM) 
(Invitrogen) supplemented with 5% FBS and 10 nM 
DHT. RWPE-1 cells were maintained in Keratinocyte-
SFM medium (Invitrogen), and 3T3 cells were grown in 
Dulbecco’s Modified Eagle Medium (DMEM, Invitrogen) 
supplemented with 10% newborn calf serum (NCS, 
Invitrogen). For androgen-mediated upregulation of FASN 
expression and lipogenesis [39, 40], cells were grown 
after seeding in phenol-red free RPMI-1640 with 5% 
FBS for an additional 48 h in phenol-red free RPMI-1640 
supplemented with 5% charcoal-stripped serum (CSS) 
(Invitrogen). After this, medium was supplemented with 
androgens (1 nM mibolerone or 10 nM DHT), and cells 
were grown for another 72 h before treatment with TCS 
or C75 for 48 h.
Live imaging and Alamar Blue assay
Cells were seeded in 96-well plates at 4.0 x 103 
(LNCaP, C4-2B, 22RV1, LAPC4) or 3.0 x 103 cells per 
well (PC-3, RWPE-1, WPMY-1, BPH-1 and NIHT3T) 
and grown to 20% confluence before addition of the 
indicated compounds. For rescue experiments, palmitate 
(Sigma) was conjugated with FA-free BSA (Roche 
Applied Science) at a 6:1 ratio for 1 h at 37°C and diluted 
into growth medium. Growth as a function of increasing 
confluence was measured in real-time by phase contrast 
microscopy with the IncuCyte FLR system (Essen 
BioScience). Images were taken with a 10x objective at 2 
h intervals from 3 separate wells per treatment, and mean 
±SD of confluence percentages was computed. For Alamar 
Blue endpoint assays, cells were seeded into 96-well tissue 
culture plates and treated with the indicated compounds 
as described above. Metabolic activity was measured 
with Alamar Blue after 48 h of treatment according to 
the manufacturer’s instruction (Invitrogen, USA). Kinetic 
analysis and calculation of IC50 were performed with 
GraphPad Prism (GraphPad Software).
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Fluorescence microscopy
LNCaP cells were seeded in 24-well plates on cover 
slips at 1.0 x 104 in phenol-red free RPMI-1640 medium 
supplemented with 5% FBS before treatment with TCS 
for 48 h. Cells were washed with 1 ml PBS, fixed for 20 
min in 4% paraformaldehyde on ice and washed again 
with 1 ml of PBS. Finally, cellular lipids were stained 
with 0.1 µg/ml Nile Red (Sigma), and nuclear DNA 
was counterstained with 1 µg/ml 4’,6-diamidino-2-
phenylindole (DAPI) (Invitrogen). Cells were imaged on 
a Nikon Eclipse Ti fluorescent microscope equipped with 
NIS Elements imaging software (Nikon). Fluorescence 
of Nile Red was excited at 488 nm, and emission was 
acquired at 530 nm with a FITC filter and at 610 nm with 
a Texas Red filter.
Lipid content
Cells were seeded at 2.0 x 105 cells per well in 
6-well plates in phenol-red free RPMI-1640 medium 
supplemented with 5% FBS for 48 h. After treatment 
for 48 h with TCS or C75, cells were harvested with 
trypsin, washed with 1 ml of PBS and fixed in 4% 
paraformaldehyde for 20 min on ice. Cells were washed 
again with 1 ml of PBS and finally resuspended in 0.2 
ml of PBS. For androgen treatment, cells were seeded at 
8.0 x 104 cells per well in 6-well plates and processed as 
described above. A 96-well plate was set up with 40 µl of 
cell suspension in a total volume of 100 µl with PBS, and 
lipids were stained with Nile Red at a final concentration 
of 0.5 µg/ml. For normalisation, 40 µl of cell suspension 
in a total volume of 100 µl with TE (10 mM Tris-HCl 
pH 7.5, 1 mM EDTA) was mixed with 0.5 µl of Quant-
iT PicoGreen DNA stain (Invitrogen) according to the 
manufacturer’s instructions. Fluorescence of Nile Red-
stained neutral lipids (485 nm/520 nm) and polar lipids 
(485 nm/620 nm) and Quant-iT PicoGreen-stained DNA 
(485 nm/520 nm) was measured in a FLUOstar Omega 
plate reader (BMG Labtech). Fluorescence intensities were 
normalized according to the DNA content and calculated 
as fold-changes relative to control. For analysis by flow 
cytometry, cells were seeded and harvested as described 
above and directly stained with Nile Red (0.5 µg/ml). The 
median fluorescence intensity of 20,000 cell events was 
measured at 520 nm with a FITC filter on a FACSCanto 
(BD Biosciences). 
Western blot
Cells were plated at 1.5 x 105 cells per well in 
6-well plates in phenol-red free RPMI-1640 medium 
supplemented with 5% FBS for 48 h and treated for the 
indicated times. Cells were lyzed in 120 µl RIPA buffer 
supplemented with protease and phosphatase inhibitors as 
described previously [51]. Cell lysates (30ug/ lane) were 
separated by SDS-polyacrylamide gel electrophoresis, and 
proteins were transferred to PVDF membrane (Millipore). 
Primary antibodies were from Cell Signaling Technologies 
and used as recommended by the manufacturer; FASN 
(#3189), ACC (#3676), P(Ser79)-ACC (#3661), PARP 
(#9542), AMPKα (#2793), P(Thr172)-AMPKα (#2531), 
eIF2α (#2103). Beta-Actin antibody (sc-47778, Santa 
Cruz Biotechnology) or eIF2α (#2103, Cell Signaling 
Technologies) were used to normalize protein loading. 
PVDF membranes were probed with the appropriate 
horseradish peroxidase-conjugated secondary antibody 
(GE Healthcare) and visualized with a chemiluminescence 
reaction system (Immobilon Western Chemiluminescent 
HRP Substrate, Merck Millipore) and documented on 
a ChemiDoc XRS system (Bio-Rad). Proteins were 
quantitated using Image Lab™ software (Bio-Rad), 
normalized to the respective loading control, and expressed 
relative to the control treatment. Phosphorylation levels 
were calculated relative to the normalized total amount of 
the respective protein. 
Flow cytometry
Cells were seeded at 2.0 x 105 cells per well in 
6-well plates in phenol-red free RPMI-1640 medium 
supplemented with 5% FBS for 48 h. After treatment 
for 48 h with TCS or C75, cells were harvested with 
trypsin, washed with 1 ml of PBS and fixed in 1 ml of 
70% ethanol for 60 min at -20°C. Cells were washed in 1 
ml of PBS, resuspended in 0.5 ml of PBS supplemented 
with 10 µg/ml propidium iodide (PI) (Sigma) and 30 µg/
ml DNAse-free RNAse A (Sigma) and incubated over 
night at 4°C. Samples were analyzed on a FACSCanto 
(BD Biosciences), where 20,000 events were counted after 
exclusion of cell doublets and polyploid cell populations. 
DNA histograms were analyzed with ModFit LT (Verity 
Software House). For the detection of apoptosis, samples 
were prepared as above except that cells were not fixed in 
70% ethanol. Instead, 1 x 105 cells were resuspended in 1 
x Annexin V binding buffer (10 mM Hepes-NaOH pH 7.4, 
150 mM NaCl, 2.5 mM CaCl2) containing 2 µl of 0.15 mg/
ml FITC-conjugated Annexin V (BioVision) and PI at 5 
µg/ml and incubated for 5 min in the dark. After electronic 
compensation, FITC and PI fluorescent intensities were 
measured for 20,000 cell events on a FACSCanto (BD 
Biosciences) and analyzed with FACSDiva software (BD 
Biosciences).
Quantitative real-time PCR
LNCaP cells were seeded at a density of 1 × 105 
cells/well in a 6-well plate. After 48 h, cells were treated 
with the indicated inhibitors. After an additional 48 h, total 
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RNA was obtained using the RNeasy mini kit (Qiagen) 
according to the manufacturer’s instructions. cDNA 
was prepared from 2 µg total RNA with Superscript III 
(Invitrogen). qRT-PCR was performed with SYBR Green 
PCR Master Mix (Invitrogen) on a 7900HT Fast Real-
Time PCR System (Applied Biosystems). The mRNA 
expression levels were calculated according to the ΔΔCt 
method and normalized relative to the expression levels 
of the house keeping gene (RPL32) of the respective 
treatment and expressed as fold change relative to the 
control (DMSO). Statistical significance was analyzed 
with GraphPad Prism (GraphPad Software) by one-way 
ANOVA with Bonferroni post-tests. The sequences of the 
primers used are listed in the Supporting Information.
Synthesis of TCS derivatives
The chemical synthesis and validation of the TCS 
derivatives is described in the Supplemental Material. 
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